A collaboration between two of the nation’s preeminent medical institutions has yielded what may prove to be the most consequential advance in decades against a malignancy that has long defied early detection: pancreatic cancer. Researchers at the University of Pennsylvania’s Perelman School of Medicine and the Mayo Clinic in Rochester, Minnesota, have developed a blood test that correctly distinguished pancreatic cancer cases from non-cases 91.9 percent of the time across all stages, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The study, supported by the National Institutes of Health, was released on January 29, 2026, and has drawn sustained attention from the scientific community for its potential to transform clinical practice against one of medicine’s most intractable foes.
Pancreatic ductal adenocarcinoma — the form of the disease that accounts for roughly ninety-five percent of pancreatic cancer diagnoses, according to the AACR — is distinguished by a grim arithmetic that has scarcely budged in a generation. The five-year survival rate for pancreatic cancer has stalled at thirteen percent for the third consecutive year, according to the Pancreatic Cancer Action Network’s 2026 report. In 2026, an estimated 67,530 Americans will be diagnosed with the disease and 52,740 are expected to die from it, as reported by the American Cancer Society. The disease remains the third leading cause of cancer-related death in the United States, trailing only lung and colorectal cancers, and it is projected to claim the second position by 2030, according to the Hirshberg Foundation for Pancreatic Cancer Research. When detected at a localized, early stage, the five-year relative survival rate is approximately forty-four percent; once the cancer has metastasized, that figure plummets to three percent, according to the AACR. The disparity in those numbers constitutes both the tragedy and the opportunity: most cases are diagnosed only after the disease has spread beyond surgical reach.
It is precisely this diagnostic void that the new research addresses. The investigative team, led by Dr. Kenneth S. Zaret, a professor of cell and developmental biology at the Perelman School of Medicine, analyzed plasma samples from 672 patients drawn from two independent cohorts — 537 from the Mayo Clinic and 135 from the Hospital of the University of Pennsylvania, as reported by the NIH. The cohorts included patients with confirmed pancreatic cancer, healthy individuals, and patients with benign pancreatic disease such as pancreatitis, enabling the researchers to evaluate the test’s capacity to differentiate malignancy from conditions that frequently mimic it.
The team’s approach built upon earlier work with two blood biomarkers already known to the oncology field: carbohydrate antigen 19-9, or CA19-9, which is widely used to monitor treatment response in diagnosed pancreatic cancer patients, and thrombospondin 2, or THBS2, a protein expressed in pancreatic tumor tissue. Neither proved adequate as a screening instrument. CA19-9 can be elevated in patients with benign conditions such as pancreatitis and bile duct obstruction, while some individuals do not produce the marker at all due to genetic factors, as the NIH confirmed. The inadequacy of existing markers has left pancreatic cancer as the only one among the five most lethal cancers in the United States without a standard screening strategy, according to the Pancreatic Cancer Action Network.
By analyzing banked blood samples using mass spectrometry and ELISA assays, the research team identified two novel biomarker proteins — aminopeptidase N, known as ANPEP, and polymeric immunoglobulin receptor, known as PIGR — that were elevated in the blood of early-stage pancreatic cancer patients compared with healthy volunteers, as reported by both the NIH and ScienceDaily. These newly identified markers showed clear differences between cancer patients and healthy individuals, according to ScienceDaily. When combined with CA19-9 and THBS2 into a four-marker panel, the diagnostic power increased substantially. The combined test correctly distinguished pancreatic cancer cases from non-cases 91.9 percent of the time for all stages combined at a false positive rate of five percent, according to the NIH. For early-stage cancers — stage I and stage II — the panel identified 87.5 percent of cases, the NIH confirmed. By comparison, testing for CA19-9 alone identified only 82.7 percent of cases overall and 76.2 percent of early-stage cases, as reported by the AACR.
The area under the receiver-operating characteristic curve — a standard measure of diagnostic test performance where 1.0 represents a perfect score — reached 0.97 and 0.96 for the Penn and Mayo cohorts respectively when comparing early-stage cancer against healthy controls, according to Penn Medicine. The panel also distinguished cancer from benign pancreatic conditions with an AUC of 0.87 for early-stage disease and 0.91 for all stages in the Mayo cohort, Penn Medicine reported. This capacity to separate malignant from benign disease represents a critical advance, as inflammation-related conditions have historically confounded screening efforts, according to Inside Precision Medicine.
“By adding ANPEP and PIGR to the existing markers, we’ve significantly improved our ability to detect this cancer when it’s most treatable,” Dr. Zaret said, as quoted by the NIH. He further explained the panel’s advantage, noting, according to the AACR, that the addition of the two new proteins helps overcome limitations in patients who genetically underexpress CA19-9 or whose tumors present as different molecular subtypes, thereby reducing the number of missed cancer cases while keeping false positives low.
The investigators have been forthright about the work that remains. The study was retrospective in design, meaning the researchers already knew the diagnosis status of the patients whose blood they analyzed. Dr. Zaret acknowledged this limitation directly. “Our retrospective study findings warrant further testing in larger populations, particularly in people before they show symptoms,” he said, as quoted by the NIH. He called for “prediagnostic” studies to determine whether the test could serve as a screening tool for individuals at elevated risk — those with a family history, genetic screening results indicating susceptibility, or a personal history of pancreatic cysts or pancreatitis. The cohorts also did not include individuals at increased risk for pancreatic cancer, such as those with germline BRCA mutations or new-onset diabetes, introducing a potential bias in test performance, as the AACR noted.
The strategic significance of this research to the health of the American people cannot be overstated. A low-cost, minimally invasive blood test that reliably identifies early pancreatic cancer would represent a paradigm shift in oncological practice — moving from late-stage reaction to earlier, more precise intervention, as Inside Precision Medicine observed. The study was supported by multiple NIH grants spanning the National Cancer Institute, the National Center for Advancing Translational Sciences, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Office of the Director, in addition to the Lustgarten Foundation, the Penn Pancreatic Cancer Research Center, the Centene Foundation, and the Mayo Clinic Comprehensive Cancer Center. Mayo Clinic and Exact Sciences maintain an intellectual property development agreement related to the research, according to PubMed.
The American biomedical research enterprise — anchored by NIH funding, sustained by the collaborative architecture of the nation’s university hospitals and research clinics, and advanced by investigators such as Dr. Zaret and his colleagues — has produced here a genuinely promising instrument against a disease that has resisted meaningful therapeutic progress for decades. Whether the four-marker panel proves durable in the prospective trials that must follow will determine whether the lethal arithmetic of pancreatic cancer can at last be altered. For the tens of thousands of Americans who will receive a diagnosis this year, the urgency of that determination requires no elaboration.